Loading...
•
Dec 31, 2023
Cytek Biosciences Q4 2023 Earnings Report
Reported strong fourth quarter performance driven by revenue increase.
Key Takeaways
Cytek Biosciences reported a strong fourth quarter with a 21% increase in total revenue, reaching $58.6 million. The company's strategic execution and agility contributed to navigating the challenging macroeconomic environment. Net income for the quarter was $6.3 million, compared to $3.7 million in the same period of the prior year.
Total revenue reached $58.6 million, a 21% increase year-over-year.
Organic revenue grew to $48.8 million, a 1% increase year-over-year.
Gross profit was $33.7 million, a 15% increase year-over-year.
Net income increased to $6.3 million, compared to $3.7 million in the prior year.
Forward Guidance
Cytek Biosciences anticipates total revenue for the year ending December 31, 2024, to range from $203 million to $213 million, indicating a growth of 5% to 10% compared to the year ending December 31, 2023, with the assumption of stable currency exchange rates. The company also expects to achieve positive net income for the year ending December 31, 2024.
Positive Outlook
- Expects total revenue for 2024 to be in the range of $203 million to $213 million.
- Projects revenue growth of 5% to 10% over 2023.
- Assumes no change in currency exchange rates.
- Anticipates reporting positive net income for the year ended December 31, 2024.
- Focuses on effectively driving strategic growth and delivering long-term profitability.
Challenges Ahead
- Guidance assumes no change in currency exchange rates.
- Future performance is subject to global economic and market conditions.
- Company's ability to accurately forecast customer demand and adoption of its products.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...